5541
document
Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects . OBJECTIVE Consumption of soy protein has recently been shown to improve the blood lipid levels in nondiabetic subjects . The purpose of this study was to evaluate if a dietary supplement of soy protein , isoflavones , and cotyledon fiber ( Abalon ) affects cardiovascular risk markers , blood glucose , and insulin levels in type 2 diabetic subjects . RESEARCH DESIGN AND METHODS Twenty type 2 diabetic subjects participated in a crossover trial . They were randomized to double-blind supplementation for 6 weeks with Abalon ( soy protein [ 50 g/day ] with high levels of isoflavones [ minimum 165 mg/day ] and cotyledon fiber [ 20 g/day ] ) or placebo ( casein [ 50 g/day ] and cellulose [ 20 g/day ] ) , separated by a 3-week wash-out period . RESULTS The results are expressed as means +/- SD . The percentage mean treatment difference between Abalon and placebo demonstrated significantly lower mean values after Abalon for LDL cholesterol ( 10 +/- 15 % , P < 0.05 ) , LDL/UHDL ratio ( 12 +/- 18 % , P < 0.05 ) , apolipoprotein ( apo ) B100 ( 30 +/- 38 % , P < 0.01 ) , triglycerides ( 22 +/- 10 % , P < 0.05 ) , and homocysteine ( 14 +/- 21 % , P < 0.01 ) , whereas the total cholesterol value tended to be less significant but still lower ( 8 +/- 15 % , P < 0.08 ) . No change occurred in HDL cholesterol , apo B100/apo A1 ratio , plasminogen activator inhibitor 1 , factor VIIc , von Willebrand factor , fibrinogen , lipoprotein ( a ) , glucose , HbA1c , or 24-h blood pressure . CONCLUSIONS These results indicate beneficial effects of dietary supplementation with Abalon on cardiovascular risk markers in type 2 diabetic subjects . This improvement is seen even in individuals with near-normal lipid values .
5542
Intervention_Pharmacological
soy-based dietary supplement
5543
Intervention_Pharmacological
soy protein
5544
Intervention_Pharmacological
isoflavones
5545
Intervention_Pharmacological
cotyledon fiber ( Abalon )
5546
Intervention_Pharmacological
6 weeks with Abalon ( soy protein
5547
Intervention_Pharmacological
isoflavones
5548
Intervention_Pharmacological
cotyledon fiber
5549
Intervention_Control
placebo
5550
Intervention_Pharmacological
Abalon
5551
Intervention_Control
placebo
5552
Intervention_Pharmacological
Abalon
5553
Intervention_Pharmacological
Abalon
5554
Outcome_Physical
lipid levels
5555
Outcome_Physical
cardiovascular risk markers
5556
Outcome_Physical
blood lipid levels
5557
Outcome_Physical
cardiovascular risk markers
5558
Outcome_Physical
blood glucose
5559
Outcome_Physical
insulin levels
5560
Outcome_Physical
LDL cholesterol
5561
Outcome_Physical
LDL/UHDL ratio
5562
Outcome_Physical
apolipoprotein
5563
Outcome_Physical
triglycerides
5564
Outcome_Physical
homocysteine
5565
Outcome_Physical
total cholesterol value
5566
Outcome_Physical
HDL cholesterol
5567
Outcome_Physical
apo B100/apo A1 ratio
5568
Outcome_Physical
plasminogen activator inhibitor 1
5569
Outcome_Physical
factor VIIc
5570
Outcome_Physical
von Willebrand factor
5571
Outcome_Physical
fibrinogen
5572
Outcome_Physical
lipoprotein ( a )
5573
Outcome_Physical
glucose
5574
Outcome_Physical
HbA1c
5575
Outcome_Physical
24-h blood pressure
5576
Outcome_Physical
cardiovascular risk markers
5577
Participant_Condition
type 2 diabetic subjects .
5578
Participant_Sample-size
Twenty
5579
Participant_Condition
type 2 diabetic